Q3 2021 Investor Relations Results
Participants
Company overview
Pharmaceuticals
Oncology
Financial review
Conclusion
Appendix
References
2021 Novartis full year guidance
Barring unforeseen events; growth vs. PY in cc
Sales expected to grow low to mid single digit
Group
Core Oplnc expected to grow mid single digit, ahead of sales
Innovative
Medicines
Sales expected to grow mid single digit
Core Oplnc revised upwards from expected to "grow mid to high single digit" to "grow high single digit"
Sales expected to decline low to mid single digit
Sandoz
Core Oplnc revised downwards from expected to "decline low to mid-teens” to “decline mid to high teens❞
Key assumptions
Continuation of the return to normal global healthcare systems including prescription dynamics, in the remainder of the year.
In addition, we assume that no GilenyaⓇ and no SandostatinⓇ LAR generics enter in 2021 in the US
41 Investor Relations | Q3 2021 Results
NOVARTIS | Reimagining MedicineView entire presentation